Seventy-nine cases of tislelizumab-related adverse reactions

doi:10.19803/j.1672-8629.20240261

Abstract

Abstract: Objective To analyze the regularity and clinical characteristics of adverse drug reactions (ADR) induced by tislelizumab in order to provide references for safe and rational drug use. Methods Seventy-nine reports of adverse reactions related to tislelizumab submitted by our hospital to the national ADR Monitoring System from January 1, 2020 to March 31, 2024 were retrospectively analyzed, involving patients' demographics, types of drugs used, times of adverse reactions, clinical presentations, organs and/or systems involved, severity, management and outcomes, causality assessment, and off-label use. Results Among these cases of tislelizumab-related adverse reactions, 88.61% occurred after one to five medication cycles. Affecting multiple organs and systems, the main manifestations included bone marrow suppression, skin toxicity, thyroid dysfunction, and liver function abnormalities. Myasthenic syndrome and anaphylactic shock were serious ADR not specified in drug instructions. After discontinuation of the drug and symptomatic treatment, most of the cases improved. Conclusion A few severe adverse reactions of tislelizumab can lead to life-threatening consequences. Close monitoring during clinical use is recommended, with timely symptomatic treatment to reduce severe adverse reactions.

Key words: tislelizumab, immune checkpoint inhibitors, adverse drug reaction, bone marrow suppression, myasthenic syndrome, anaphylactic shock, safety

CLC Number:

WANG Ying, HUANG Shan, SHENG Qinyong, LIAN Xia, CHANG Ying, JIANG Yan, LIN Bing, HUANG Aiwen. Seventy-nine cases of tislelizumab-related adverse reactions[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1148-1153.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240261

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I10/1148

References

[1] YI M, ZHENG XL, NIU MK, et al.Combination strategies with PD-1/PD-L1 blockade: current advances and future directions[J]. Mol Cancer, 2022, 21(1): 28-54.
[2] LEE A, KEAM S.Tislelizumab: first approval[J]. Drugs, 2020, 80(6): 617-624.
[3] ZHANG T, SONG X, XU L, et al.The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions[J]. Cancer Immunol Immunother, 2018, 67(7): 1079-1090.
[4] ZHANG L, GENG Z, HAO B, et al.Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody[J]. Cancer Control, 2022, 29(8): 1-14.
[5] YI L, QING L, LIN H.A programmed death receptor-1 inhibitor-tislelizumab[J]. Clinical Medication Journal(临床药物治疗杂志), 2022, 20(1): 37-42.
[6] Medical Dictionary for Regulatory Activities. MedDRA 25.1[EB/OL]. (2022-09-06) [2024-03-01]. https://www.meddra.org.
[7] National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE 5.0) [EB/OL]. (2017-11-27)[2023-10-15]. http://guide.medlive.cn/.
[8] TANG YD, MENG L, WU YY, et al.Analysis of adverse drug events of programmed death receptor 1/programmed death receptor ligand 1 inhibitors[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2022, 38(19): 2351-2355.
[9] GAO ZM, QI NN, QIN X, et al.The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: a single-center study based on propensity score matching[J]. Cancer Med, 2023, 12(24): 22071-22080.
[10] GUO QL, JIN LL, ZHANG TT, et al.Literature analysis of cutaneous adverse reactions induced by tislelizumab[J]. Cutan Ocul Toxicol, 2024, 43(1): 52-57.
[11] ZHU H, YUAN YF, XU Y.Literature analysis of severe immune-related adverse skin reactions induced by tislelizumab[J]. Practical Pharmacy And Clinical Remedies(实用药物与临床), 2023, 26(10): 909-913.
[12] BRAHMER JR, ABU-SBEIH H, ASCIERTO PA, et al.Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events[J]. Journal for Immunotherapy of Cancer, 2021, 9(6): e002435.
[13] PETROS F, LUCIA AP, JAMES C, et al.Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms[J]. Immunology: An Official Journal of the British Society for Immunology, 2020, 159(2): 167-177.
[14] AFFOLTER T, LLEWELLYN HP, BARTLETT DW, et al.Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice[J]. PLoS One, 2019, 14(5): e0217276.
[15] ZHANG J, ZHANG LL, LI X.Analysis of immune-related adverse events of tirelizumab in 424 cases of cancer patients[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(4): 435-439.
[16] HUO L, WANG C, DING H, et al.Severe thyrotoxicosis induced by tislelizumab: a case report and literature review[J]. Front Oncol, 2023, 13(10): 1190491.
[17] KHUNGER M, RAKSHIT S, PASUPULETI V, et al.Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a systematic review and Meta-analysis of trials[J]. Chest, 2017, 152(2): 177.
[18] YIN J, WU Y, YANG X, et al.Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism[J]. Front Immunol, 2022, 13(4): 830631.
[19] WANG S, PENG D, ZHU H, et al.Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: a case report and literature review[J]. Front Oncol, 2022, 12(11): 1053370.
[20] LIN XY, HUA WA, JING Y.A case report of myasthenia gravis caused by tislelizumab[J]. China Medicine(中国医药), 2023, 18(11): 1726-1729.
[21] HUANG Y, CHEN Y, LIN W, et al.Immune checkpoint inhibitor-induced myasthenia gravis[J]. Front Neurol, 2020, 11(16): 634-644.
[22] ZHAO ZY, ZHANG CL, ZHOU L, et al.Immune checkpoint inhibitors and neurotoxicity[J]. Curr Neuropharmacol, 2021, 19(8): 1246-1263.
[23] HAJIHOSSAINLOU B, VASILEVA A, MANTHRI S, et al.Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern[J]. BMJ Case Rep, 2021, 14(8): 764-773.
[24] ALDRICH J, PUNDOLE X, TUMMALA S, et al.Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors[J]. Arthritis Rheumatol, 2021, 73(5): 866-874.
[25] KONG QL, WANG H, REN X, et al.Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA adverse event reporting system[J]. Cancer Medicine, 2023, 12(19): 19491-19499.
[26] SCHNEIDER BJ, NAIDOO J, SANTOMASSO BD, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update[S]. Wolters Kluwer Health, 2021.
[27] Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) immune checkpoint inhibitor-related toxicity management guidelines(中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南) [M]. Beijing: People's Medical Publishing House, 2023.
[28] TSUJIMURA Y, OBATA K, MUKAI K, et al.Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis[J]. Immunity, 2008, 28(4): 581-589.
[29] NI CY, ZHANG L.A case of anaphylactic shock induced by tislelizumab[J]. Herald of Medicine(医药导报), 2023, 42(10): 1576-1577.